The frequency of the EE genotype, which has the glutamic acid on both chromosomes, was significantly increased in RR-MS patients compared to controls (59.8% vs. 49.3%, p < 0.0001) [57], suggesting that decreased Glo-1 activity can contribute to increased MGO-derived AGE-levels in MS patients, compared to controls. Here, GLO1 is linked to myeloid sarcoma.